On June 9, 2021 Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, reported the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer (Press release, Palleon Pharmaceuticals, JUN 9, 2021, View Source [SID1234583779]). Dr. Feltquate is an accomplished development leader with significant industry experience in immuno-oncology clinical development, translational medicine, and diagnostic assay advancement.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We’re delighted to welcome David at such a pivotal moment in Palleon’s growth, as we prepare to file an IND to advance our first therapeutic candidate into the clinic later this year," said Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon. "David’s extensive expertise in the development of industry-leading immuno-oncology therapeutics, alongside his training in immunology and oncology, make him a uniquely qualified leader of clinical development for Palleon’s pipeline of promising glyco-immunology therapeutics."
Prior to joining Palleon, Dr. Feltquate was the Global Head of Hematology Development and Chair of the Precision Medicine Leadership Team at Novartis. Previously, he held numerous leadership positions at BMS including Head of Oncology Early Clinical Development and Development Leader for Ipilimumab/Nivolumab Life Cycle Management. As the Nivolumab Clinical Head, Dr. Feltquate was responsible for the development of the first PD1 inhibitor from proof of concept through initial registrations in non-small cell lung cancer, melanoma, and renal cell carcinoma. Dr. Feltquate earned a B.S. in biology from the Massachusetts Institute of Technology and an M.D./Ph.D. (immunology) from University of Massachusetts Medical School. He completed internal medicine training at Dartmouth Hitchcock Medical Center and medical oncology training at Memorial Sloan Kettering Cancer Center.
"Our field has only scratched the surface of the promise of immuno-oncology to treat cancers that are untreatable today. Palleon is advancing an incredibly novel approach to unleashing the immune system to fight cancer, and the company’s platforms have additional potential to treat inflammatory diseases," said Dr. Feltquate. "I’m honored to join this pioneering team in progressing the first glyco-immunology therapeutic candidates through clinical trials, with the goal of delivering new treatment options for patients with serious diseases."